Search - tctmd.com

Displaying 521 - 540 of 739

Sort: Relevancy | Date

News Conference News ACC 2018

SECURE-PCI Comes Up Short for Statin Preloading in ACS Patients

Michael O'Riordan

March 11, 2018

News Conference News ACC 2018

ACC 2018, Day Two: Antiplatelets in ACS, Dabigatran in Noncardiac Surgery, and More

Shelley Wood

March 11, 2018

News Conference News ACC 2018

ODYSSEY Delivers a Win for Alirocumab in ACS, With a Signal of Survival Benefit

Michael O'Riordan

March 10, 2018

News Conference News ACC 2018

ACC 2018, Day One: Live From Orlando! The ODYSSEY Begins

Shelley Wood

March 10, 2018

News Daily News

Less Aggressive HbA1c Targets Recommended by American College of Physicians

Michael O'Riordan

March 06, 2018

News Conference News ACC 2018

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

Shelley Wood

March 05, 2018

News Daily News

No Cardiovascular Benefit With Omega-3 Fatty Acid Supplements: Meta-analysis

Michael O'Riordan

February 02, 2018

News Daily News

TCTMD’s Top 10 Most Popular Stories for January 2018

Shelley Wood

January 31, 2018

News Conference News ISC 2018

COMPASS Analysis Explores Impact of Low-Dose Rivaroxaban Plus Aspirin on Stroke

Todd Neale

January 25, 2018

News Daily News

Symptomatic Myocardial Ischemia but No Obstructive CAD: Some Drugs Work, Others Don’t, Review Finds

Caitlin E. Cox

January 18, 2018

News Daily News

NOACs May Carry Lower Risk of Intraocular Hemorrhage Than Warfarin

L.A. McKeown

January 02, 2018

News Daily News

Subclinical Atherosclerosis Evident in Half of Adults Without CVD Risk Factors

Michael O'Riordan

December 12, 2017

News Daily News

USPSTF Upholds Stance Against Hormone Therapy to Prevent Chronic Diseases in Menopausal Women

Caitlin E. Cox

December 12, 2017

News Daily News

It’s Official: Evolocumab Gains Claim for CVD Event Reduction

Michael O'Riordan

December 04, 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for November 2017

Shelley Wood

November 29, 2017

News Conference News AHA 2017

Diabetes Drugs Show Benefit in PAD, but Only Mixed Results in Primary Prevention of CV Events

Michael O'Riordan

November 17, 2017

News Conference News AHA 2017

‘De-escalating’ P2Y12 Inhibition Possible in Acute MI Patients: PRAGUE-18

Michael O'Riordan

November 15, 2017

News Conference News AHA 2017

Low-Dose Rivaroxaban Plus Aspirin Lowers Some Costs in COMPASS, but Full Economic Impact Unclear

Todd Neale

November 14, 2017

News Conference News AHA 2017

Two FOURIER Subgroup Analyses Show Added Benefit of Evolocumab in Those With PAD, Prior MI

Yael L. Maxwell

November 13, 2017

News Conference News AHA 2017

CANTOS: Big Drop in CVD Events Among Canakinumab Responders

Michael O'Riordan

November 13, 2017

Advertisement

SECURE-PCI Comes Up Short for Statin Preloading in ACS Patients

ACC 2018, Day Two: Antiplatelets in ACS, Dabigatran in Noncardiac Surgery, and More

ODYSSEY Delivers a Win for Alirocumab in ACS, With a Signal of Survival Benefit

ACC 2018, Day One: Live From Orlando! The ODYSSEY Begins

Less Aggressive HbA1c Targets Recommended by American College of Physicians

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

No Cardiovascular Benefit With Omega-3 Fatty Acid Supplements: Meta-analysis

TCTMD’s Top 10 Most Popular Stories for January 2018

COMPASS Analysis Explores Impact of Low-Dose Rivaroxaban Plus Aspirin on Stroke

Symptomatic Myocardial Ischemia but No Obstructive CAD: Some Drugs Work, Others Don’t, Review Finds

NOACs May Carry Lower Risk of Intraocular Hemorrhage Than Warfarin

Subclinical Atherosclerosis Evident in Half of Adults Without CVD Risk Factors

USPSTF Upholds Stance Against Hormone Therapy to Prevent Chronic Diseases in Menopausal Women

It’s Official: Evolocumab Gains Claim for CVD Event Reduction

TCTMD’s Top 10 Most Popular Stories for November 2017

Diabetes Drugs Show Benefit in PAD, but Only Mixed Results in Primary Prevention of CV Events

‘De-escalating’ P2Y12 Inhibition Possible in Acute MI Patients: PRAGUE-18

Low-Dose Rivaroxaban Plus Aspirin Lowers Some Costs in COMPASS, but Full Economic Impact Unclear

Two FOURIER Subgroup Analyses Show Added Benefit of Evolocumab in Those With PAD, Prior MI

CANTOS: Big Drop in CVD Events Among Canakinumab Responders

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content